Xiao-Peng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiao-Peng Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Fang Liu
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
1 shared publication - Jia-Min Li
Department of Gastroenterology , Union Hospital , Tongji Medical College , Huazhong University of Science and Technology , Wuhan , China , tjmu.edu.cn
1 shared publication - Junrong Li
Department of Gastroenterology , Union Hospital , Tongji Medical College , Huazhong University of Science and Technology , Wuhan , China , tjmu.edu.cn
1 shared publication - Liangru Zhu
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Qi Yu
Department of Gastroenterology , Union Hospital , Tongji Medical College , Huazhong University of Science and Technology , Wuhan , China , tjmu.edu.cn
1 shared publication - Qian-Xi Xia
Department of Gastroenterology , Union Hospital , Tongji Medical College , Huazhong University of Science and Technology , Wuhan , China , tjmu.edu.cn
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , 6629562
CAR‐Cell Therapy for Autoimmune Diseases: From the Laboratory to Clinical Practice
Autoimmune diseases (AIDs) are characterized by a breakdown in immune tolerance, wherein the patient’s immune system fails to recognize self‐tissues and subsequently attacks the body’s organs and tissues. Although there are many therapeutic medicines targeting the pathogenic mechanisms, there is currently a lack of curative or long‐term symptom control options. Chimeric antigen receptor (CAR) cells are engineered cells that express multifunctional synthetic receptors. These CAR cells specifically target killer pathogenic immune cells and offer a novel approach to treating AIDs by modulating the immune microenvironment. Recent studies have demonstrated satisfactory outcomes with this method in managing autoimmune conditions. In our review paper, we provide a comprehensive summary of previous cases utilizing CAR cell therapy for AIDs. We hope that our review will provide clinicians with more options for the treatment of AIDs.
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , 6629562
Open AccessCAR‐Cell Therapy for Autoimmune Diseases: From the Laboratory to Clinical Practice
Autoimmune diseases (AIDs) are characterized by a breakdown in immune tolerance, wherein the patient’s immune system fails to recognize self‐tissues and subsequently attacks the body’s organs and tissues. Although there are many therapeutic medicines targeting the pathogenic mechanisms, there is currently a lack of curative or long‐term symptom control options. Chimeric antigen receptor (CAR) cells are engineered cells that express multifunctional synthetic receptors. These CAR cells specifically target killer pathogenic immune cells and offer a novel approach to treating AIDs by modulating the immune microenvironment. Recent studies have demonstrated satisfactory outcomes with this method in managing autoimmune conditions. In our review paper, we provide a comprehensive summary of previous cases utilizing CAR cell therapy for AIDs. We hope that our review will provide clinicians with more options for the treatment of AIDs.